MONTREAL, QUEBEC--(CCNMatthews - Dec. 7, 2006) - MethylGene Inc. (TSX:MYG), today announced the selection of MGCD265 as the initial clinical candidate from its multi-targeted (c-MET) kinase program. MGCD265 targets the c-MET, VEGFR1, VEGFR2, VEGFR3, Tie-2 and Ron receptor tyrosine kinases, which appear to play key roles in tumor development and blood vessel formation (angiogenesis) and tumor survival.
